ClinicalTrials.gg
RecruitingNCT07555977SUPERSTARUpdated Oct 7, 2026

SUPERSTAR: Aspiration vs. Stent Retriever in Anterior Circulation LVO

An interventional study of Super Large Bore Catheter and Stent Retriever Thrombectomy in Acute Ischemic Stroke, sponsored by Shanghai Jiao Tong University Affiliated Sixth People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 7, 2026Now RecruitingFirst site in China+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
708
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
145th of 566
708 · median 271
Started
2026
with 124 others
No phase
247 of 754
122 open now
Primary completion
2027-12
later than 256 of 399 live
Registered
678th of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 145th largest by planned enrollment of the 566 interventional ones that give a count, is one of 125 that started in 2026, is one of 247 with no phase, reaches primary completion later than 256 of the 399 other live ones, and was the 678th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

375 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, open-label, blinded-endpoint, randomized controlled trial comparing super large bore catheter aspiration versus stent retriever thrombectomy as the first-line technique for anterior circulation large vessel occlusion in acute ischemic stroke. Eligible patients with acute ischemic stroke due to internal carotid artery intracranial segment and/or middle cerebral artery M1 occlusion will be randomized 1:1 to receive either aspiration using a super large bore catheter (inner diameter ≥0.080 inch) or stent retriever thrombectomy (allowing balloon guiding catheters or intermediate catheters with inner diameter \<0.080 inch). The primary outcome is the ordinal modified Rankin Scale score at 90 days post-procedure. Key secondary outcomes include the proportion of patients with mRS 0-2 at 90 days, change in NIHSS at 24 hours and 7 days, and various angiographic and safety endpoints. The trial plans to enroll 708 patients across approximately 30 centers in China. The total study duration is 24-36 months, with each patient participating for 3 months.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Endovascular thrombectomy
  • Super Large Bore Catheter
  • Acute Ischemic Stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years;
  2. Clinically diagnosed with acute ischemic stroke, and pre-procedure imaging confirms that the culprit vessel is occlusion of the intracranial segment of the internal carotid artery and/or the middle cerebral artery M1 segment;
  3. Pre-stroke modified Rankin Scale (mRS) score of 0-1;
  4. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥ 6;
  5. Alberta Stroke Program Early CT Score (ASPECTS) ≥ 3;
  6. Time from symptom onset to initiation of endovascular treatment (arterial puncture) \< 24 hours; symptom onset time is defined as the "last known well" time;
  7. Intravenous thrombolysis and/or mechanical thrombectomy are performed according to local guidelines, and intravenous thrombolysis does not delay mechanical thrombectomy;
  8. Written is obtained from the patient or a family member.

Exclusion criteria

Exclusion Criteria:

  1. Imaging shows acute or subacute intracranial hemorrhage (excluding microbleeds);
  2. Imaging indicates an intracranial tumor (excluding meningiomas \<2 cm in diameter) or mass effect caused by a tumor, such as midline shift;
  3. Cerebral embolism caused by infection or bacterial endocarditis;
  4. The culprit vessel lesion is considered to be chronic atherosclerotic stenosis and occlusion;
  5. Pre-procedure imaging suggests that the lesion is due to dissection;
  6. Previous intracranial aneurysm or vascular malformation in the culprit vessel;
  7. Presence of a life-threatening illness within 6 months that would prevent 3-month follow-up;
  8. Pregnancy, psychiatric illness, severe hepatic or renal insufficiency, severe heart failure;
  9. Concurrent participation in another clinical drug or device study;
  10. tumor;
  11. Systemic infection;
  12. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
708 participants (estimated)

Study arms

  • Experimental
    Super Large Bore Catheter Aspiration

    A super large bore aspiration catheter with an inner diameter (ID) ≥0.080 inch is preferred as the first-line device for simple aspiration thrombectomy.

    Procedure: Super Large Bore Catheter

  • Active comparator
    Stent Retriever Thrombectomy

    Stent retriever thrombectomy is preferred as the first-line technique.

    Procedure: Stent Retriever Thrombectomy

Interventions

  • ProcedureSuper Large Bore Catheter

    The SLBC group may switch to different super large bore aspiration catheters. Once the aspiration catheter contacts the thrombus, continuous negative pressure aspiration is maintained for 1 minute. A total of at least three aspiration attempts should be performed using aspiration catheters of different inner diameters. If the catheter fails to contact the thrombus despite using different inner diameter catheters, or if complete recanalization is not achieved after three attempts, or if new embolization occurs in the M2 segment or other vascular territories, the investigator may decide, as deemed necessary, to continue attempting with the original device or to use other techniques and devices for recanalization. In cases where angiography shows that the thrombus has migrated forward and can no longer be aspirated using a super large bore catheter, and continued thrombectomy is judged necessary, other rescue techniques may be used.

    Also known as: SLBC

  • ProcedureStent Retriever Thrombectomy

    Stent retriever thrombectomy is performed as the first line approach. Allowed to employ adjunctive technology during the stent retriever passes according to physician preference, which may be combined with an aspiration catheter (inner diameter \< 0.080 inch). The use of a large-bore aspiration catheter (inner diameter \> 0.080 inch) is prohibited in this arm.

    Also known as: SRT

06

What researchers measure

Primary outcomes

  1. Ordinal modified Rankin Scale score

    The modified Rankin Scale (mRS) is a 7-level ordered categorical scale that measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. 0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. \- Moderate disability. Requires some help, but able to walk unassisted. 4. \- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. \- Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. \- Dead. The higher scores mean a worse outcome.

    Time frame: 90 days (±7 days) post-procedure

Secondary outcomes

  1. Proportion of patients with modified Rankin Scale score 0-2

    The modified Rankin Scale (mRS) is a 7-level ordered categorical scale that measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. 0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. \- Moderate disability. Requires some help, but able to walk unassisted. 4. \- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. \- Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. \- Dead. The higher scores mean a worse outcome. A modified Rankin Scale score 0-2 indicates independence.

    Time frame: 90 days (±7 days) post-procedure

  2. Other binary classifications of modified Rankin Scale score

    Modified Rankin Scale score 0-1 vs. 2-6, 0-3 vs. 4-6, 0-4 vs. 5-6, 0-5 vs. 6. The modified Rankin Scale (mRS) is a 7-level ordered categorical scale that measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. 0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. \- Moderate disability. Requires some help, but able to walk unassisted. 4. \- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. \- Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. \- Dead. The higher scores mean a worse outcome.

    Time frame: 90 ± 7 days post-procedure

  3. Change in stroke severity (National Institutes of Health Stroke Scale score)

    Change of NIHSS score at 24h from baseline. The NIHSS is a standardized, validated tool used to quantify the severity of neurological deficits in patients with acute stroke. Score range: 0 to 42 (higher scores indicate more severe stroke).

    Time frame: 24 hours post-procedure

  4. Change in stroke severity (National Institutes of Health Stroke Scale score)

    Change of NIHSS score at 7 days post-procedure or at discharge from baseline. The NIHSS is a standardized, validated tool used to quantify the severity of neurological deficits in patients with acute stroke. Score range: 0 to 42 (higher scores indicate more severe stroke).

    Time frame: 7 days post-procedure or at discharge (whichever occurs first)

Other outcomes

  1. Aspiration catheter delivery success rate

    Defined as successful delivery of the aspiration catheter to the target occluded vessel, contacting the tail of the thrombus, or contacting the tail of the stent retriever before retrieval.

    Time frame: During the procedure

  2. Final angiographic reperfusion status

    eTICI 0 - No reperfusion. eTICI 1 - Minimal reperfusion (flow past the occlusion but no distal branch filling). eTICI 2a - Reperfusion \<50% of the occluded target artery territory. eTICI 2b - Reperfusion ≥50% but \<90%. eTICI 2c - Reperfusion ≥90% (near complete, only slow flow or small distal clot). eTICI 3 - Complete (100%) reperfusion.

    Time frame: Immediately after procedure

  3. Reperfusion status after first-line technique thrombectomy

    eTICI 0 - No reperfusion. eTICI 1 - Minimal reperfusion (flow past the occlusion but no distal branch filling). eTICI 2a - Reperfusion \<50% of the occluded target artery territory. eTICI 2b - Reperfusion ≥50% but \<90%. eTICI 2c - Reperfusion ≥90% (near complete, only slow flow or small distal clot). eTICI 3 - Complete (100%) reperfusion.

    Time frame: During the procedure after the first-line technique thrombectomy

  4. First-pass successful reperfusion rate

    First-pass successful reperfusion defined as reperfusion ≥90% (eTICI 2c) after first pass.

    Time frame: During the procedure after the first thrombectomy

  5. Time from arterial puncture to successful reperfusion (≥ eTICI 2b)

    Successful reperfusion defined as reperfusion status ≥ eTICI 2b

    Time frame: During the procedure, time from puncture to successful reperfusion (≥ eTICI 2b) achieved

  6. Time from arterial puncture to successful reperfusion (≥ eTICI 2c)

    Successful reperfusion defined as reperfusion status ≥ eTICI 2c

    Time frame: During the procedure, time from puncture to successful reperfusion (≥ eTICI 2c) achieved

  7. Proportion of patients achieving reperfusion (≥ eTICI 2b) within 45 minutes of puncture

    Achieving revascularization defined as reperfusion status ≥ eTICI 2b

    Time frame: During the procedure, 45 minutes after puncture.

  8. Proportion of patients achieving reperfusion (≥ eTICI 2c) within 45 minutes of puncture

    Achieving revascularization defined as reperfusion status ≥ eTICI 2c

    Time frame: During the procedure, 45 minutes after puncture.

  9. Proportion of patients achieving revascularization (eTICI 3) within 45 minutes of puncture

    Achieving revascularization defined as reperfusion status with eTICI 3

    Time frame: During the procedure, 45 minutes after puncture.

  10. Total number of final thrombectomy passes to achieve successful recanalization

    Successful recanalization defined as reperfusion status≥ eTICI 2c)

    Time frame: During the procedure

  11. Proportion of patients with embolization to a new territory (non-culprit vascular territory)

    Embolization to a new territory not within the artery of thrombectomy

    Time frame: During the procedure

  12. Proportion of patients with distal embolization of the culprit vessel territory

    Embolization to the distal area of the culprit artery

    Time frame: During the procedure

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2027, 15 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 15 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 29, 2026
StartActual
Sep 17, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Mar 30, 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 7, 2026
Sites
1 site added — first site in China
Show site
  • Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine · Shanghai, China
Oct 7, 2026
Start date
Sep 15, 2026→Sep 17, 2026 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine · Shanghai, China
    Start date Sep 15, 2026→Sep 17, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07555977
Lead sponsor
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Responsible party
Yueqi Zhu (Chief of Radiology department, Shanghai Jiao Tong University Affiliated Sixth People's Hospital) — Principal investigator
First posted
Apr 29, 2026
Start date
Sep 17, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Yueqi Zhu, MD
Contact
zhuyueqi@sjtu.edu.cn
18930173115
Jiangshan Deng, MD
Contact
jiangshandeng@sjtu.edu.cn
18817822181
Yueqi Zhu, MD
principal investigator · Shanghai Sixth Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion